May 4, 2026 · Form 4 insider transaction
Eastling Thomas Wilson bought 92,683 shares of Gyre Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.